Retrospective Study of Ovarian Cancer Patients With Brain Metastasis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01258881
First received: December 10, 2010
Last updated: NA
Last verified: December 2010
History: No changes posted

December 10, 2010
December 10, 2010
April 2010
December 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Retrospective Study of Ovarian Cancer Patients With Brain Metastasis
Retrospective Study of Ovarian Cancer Patients With Brain Metastasis

Ovarian cancer, especially epithelial ovarian carcinoma, has the highest mortality rate among the gynecologic malignancies. The majority of patients with epithelial ovarian carcinoma are diagnosed at advanced stage which has the overall survival rates of only 19-30%. As the advance in the managements which prolonged the overall survival, metastatic lesion in rare location such as brain was noted in few patients of ovarian cancer in recent years. In the retrospective study, the investigators will review the medical records of the ovarian cancer patients with brain metastasis in the investigators hospital to investigate the incidence, clinical courses, optimal managements and possible prognostic factors in the rare condition.

The ovarian cancer patient treated at the Department of Obstetrics and Gynecology of the National Taiwan University Hospital were retrospectively collected. The cancer registration database was searched for the patients with ovarian carcinoma who brain metastases were also diagnosed. The medical records of these patients were reviewed with particular attention to the results of histo-pathological and radiologic reports. Patients with other synchronous primary brain tumor were excluded. The initial management of primary tumor, including the surgery and adjuvant chemotherapy, and the clinical courses and disease status, such as remission, recurrence and progression, were all carefully reviewed. The intra-cranial lesions were all diagnosed by imaging studies, including brain computed tomography (CT) and magnetic resonance imaging (MRI) scans. Therapeutic strategies for the metastatic lesions in the brain were also reviewed. All statistical analyses were performed using the SPSS 13.0 statistical software for Windows. P<0.05 was defined as statistical significance. Survival was measured from the time of initial diagnosis of brain metastasis until the date of death or last contact, and was presented by Kaplan-Meier curves.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

ovarian cancer patients with brain metastasis

  • Ovarian Cancer
  • Brain Metastases
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
70
December 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with ovarian cancer and brain metastasis
  • Patients ovarian cancer from National Taiwan University Hospital

Exclusion Criteria:

  • none
Female
25 Years to 80 Years
No
Contact: Wen-Fang Cheng, Professor 886-2-23123456 ext 71964 wenfangcheng@yahoo.com
Taiwan
 
NCT01258881
201004066R
No
Wen-Fang Cheng/Professor, National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Wen-Fang Cheng, Professor National Taiwan University Hospital
National Taiwan University Hospital
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP